Can brivaracetam cause a lichenoid drug eruption?

Brivaracetam and Lichenoid Dermatitis

The FDA-approved labeling for brivaracetam does not list lichenoid dermatitis or lichenoid drug eruption as a known adverse effect, and there is no published evidence linking brivaracetam to this specific cutaneous reaction 1.

Evidence Review

The provided evidence does not support an association between brivaracetam and lichenoid eruptions. The FDA drug label for brivaracetam extensively details its pharmacokinetic properties, drug interactions, and safety profile but makes no mention of lichenoid reactions or any dermatologic adverse effects resembling lichen planus 1.

Known Culprit Medications for Lichenoid Drug Eruptions

The most commonly implicated drugs in lichenoid drug eruptions include:

• Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) - accounting for 42.1% of reported cases, with lichenoid eruptions appearing as erythematous papules or plaques more frequently (30%) with anti-PD-1 therapy 2, 3
• Tyrosine kinase inhibitors - representing 12% of cases 3
• Anti-TNF-α monoclonal antibodies - accounting for 4% of cases 3, 4
• Traditional agents including gold, antimalarial drugs, β-blockers, ACE inhibitors, and angiotensin receptor blockers 4, 5
• Other antiepileptic drugs - notably, the hepatitis C protease inhibitor telaprevir has been associated with lichenoid reactions, but this is a different drug class than brivaracetam 2

Clinical Characteristics of Lichenoid Drug Eruptions

If a lichenoid eruption were to occur, key features include:

• Latency period: Mean onset of 15.7 weeks (range 0.1-208 weeks), though some cases occur years after drug initiation 3, 5
• Clinical presentation: Symmetric, erythematous, violaceous papules and plaques, often in UV-exposed areas, with significant pruritus 2, 3
• Resolution time: Median 14.2 weeks (range 0.71-416 weeks) after drug discontinuation 3

Diagnostic Approach

If lichenoid dermatitis develops in a patient taking brivaracetam, consider alternative etiologies first:

• Review all concomitant medications, particularly those with established associations (checkpoint inhibitors, TKIs, biologics, antihypertensives) 3, 4
• Consider idiopathic lichen planus as the primary diagnosis 6, 7
• Perform skin biopsy showing characteristic band-like lymphocytic infiltrate with basal membrane degeneration 2, 6
• Note that patch testing and drug-induced lymphocyte stimulation testing have low sensitivity 5

Management if Lichenoid Eruption Occurs

First-line treatment regardless of etiology:

• High-potency topical corticosteroids (clobetasol 0.05% or fluocinonide 0.05% cream/ointment) applied for 2-3 months until symptoms improve to Grade 1, then taper over 3 weeks 2, 8
• Tacrolimus 0.1% ointment as an alternative first-line option 2, 9
• Oral antihistamines for pruritus control 2

For moderate to severe disease:

• Oral prednisone or IV methylprednisolone 2
• Narrow-band UVB phototherapy if available 2
• Steroid-sparing immunosuppressants (azathioprine, cyclosporine, hydroxychloroquine, methotrexate, mycophenolate mofetil) for refractory cases 2, 8

Clinical Bottom Line

Brivaracetam is not a recognized cause of lichenoid drug eruption based on current FDA labeling and available literature. If a patient on brivaracetam develops lichenoid dermatitis, thoroughly investigate other potential culprit medications and consider idiopathic lichen planus as the more likely diagnosis 1, 3. The decision to discontinue brivaracetam should be based on a comprehensive medication review and temporal relationship assessment, recognizing that only 26% of lichenoid drug eruptions require discontinuation of the suspected agent 3.